Morepen Laboratories Limited

Morepen Laboratories Limited

Morepen Laboratories Limited has published a newspaper notice for the completion of dispatch of the notice of its 41st Annual General Meeting and the Annual Report for the financial year 2025-26.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange regarding the dispatch of letters to members whose email IDs are not registered with the company, comprising the weblink to access the Annual Report for the financial year 2025-26. The company has also announced the 41st Annual General Meeting (AGM) to be held on September 26, 2026, and proposed a final dividend of ₹ 0.20 per equity share.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange about Shareholders meeting, notice of 41st Annual General Meeting, record date and book closure.

Morepen Laboratories Limited

Morepen Laboratories Limited has published a newspaper advertisement regarding its 41st Annual General Meeting, dividend, and record date.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange about allotment of equity shares by Morepen RX Limited, a wholly owned subsidiary, to the company. The allotment of 2,00,00,000 equity shares at par, aggregating to Rs. 20,00,00,000, has strengthened the company's shareholding in MRX to 2,70,82,356 equity shares.

Morepen Laboratories Limited

Morepen Laboratories Limited has published its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, in accordance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Morepen Laboratories Limited

Morepen Laboratories Limited has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, as per SEBI Regulations and Monitoring Agency Agreement dated August 01, 2024. The report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange about Intimation of 41st Annual General Meeting scheduled to be held on September 26, 2026, and the Board of Directors have considered and approved several matters, including un-audited standalone & consolidated financial results for the quarter ended June 30, 2026, and the re-appointment of Mr. Sushil Suri as the Chairman & Managing Director of the company.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange regarding the re-appointment of Mr. Sushil Suri as Chairman & Managing Director of the company, effective from October 20, 2026. The company has also announced its un-audited standalone & consolidated financial results for the quarter ended June 30, 2026, and has set a record date for the final dividend for the financial year ended March 31, 2026. Additionally, the company has announced the extension of the approved timeline for hiving off its Medical Devices Business into a subsidiary company, Morepen Medipath Limited, and has scheduled its 41st Annual General Meeting for September 26, 2026.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange that Record date for the purpose of Final Dividend is 19-Sep-2026. The company has also approved the financial results for the quarter ended 30th June 2026, and has announced the re-appointment of Mr. Sushil Suri as the Chairman & Managing Director of the company.

Morepen Laboratories Limited

Morepen Laboratories Limited has announced its financial results for Q1 FY27, reporting its highest-ever quarterly revenue and earnings, supported by better operating leverage, improved performance on API front, strong export growth and full scale commercialization of CDMO mandate.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange about Investor Presentation

Morepen Laboratories Limited

Morepen Laboratories Limited has announced its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, and has also approved the re-appointment of its Chairman and Managing Director, Sushil Suri, for a further period of three years. The company has also fixed a record date for the final dividend for the financial year ended March 31, 2026, and has scheduled its 41st Annual General Meeting for September 26, 2026.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange about the name change of its wholly owned subsidiary company from 'Morepen Labs - FZCO' to 'Morepen Labs FZE' effective from 20th July 2026.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange about the resignation of a Director/KMP/SMP, but no further details are provided.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange regarding resignation of Mr. Bhola Prasad as General Manager Process Engineering & Technology Transfer, a functional head, being a Senior Management Personnel of the company w.e.f. July 06, 2026.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange regarding a press release dated July 01, 2026, titled Morepen starts commercial supplies under its ₹ 825 Crore CDMO mandate. The company has completed the first commercial dispatch valued at approximately ₹50 crore during Q1FY2026-27.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange about the elevation and change in designation of Mr. Sanjay Suri from Whole-time Director to Managing Director with effect from 1st July 2026, for the balance tenure of his existing term, i.e., up-to 12th August 2028.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, for the purpose of considering and approving unaudited consolidated and standalone financial results for the quarter ended on 30th June 2026.